glp-1 therapy for diabetes GLP-1-based therapies diabetes, obesity and beyond GLP-1 Drug Savings: A Complete

2021;38: e14657

Specific residues throughout the mid-region of the peptide (approximately positions 12-29) were selected and optimized to maintain GIP receptor potency while simultaneously enabling interactions with the GLP-1 and glucagon receptors

Eating disorders Pre-clinical and mechanistic studies We retrieved only a few pre-clinical and mechanistic articles relevant to GLP-1RAs for eating disorders (Supplementary Section 5)

Considering the potential of secondary bile acids to increase L-cells and GLP-1 secretion by TGR5, TGR5 agonists are promising drug candidates for increasing L-cells and GLP-1 secretion [180, 181]